Off-label use of recombinant factor VIIa in pediatric patients

Pediatrics

Volumn 129, Issue 6, 2012, Pages

  McQuilten, Zoe K ^a   Barnes, Chris ^b   Zatta, Amanda ^a   Phillips, Louise E ^a  

^a MONASH UNIVERSITY   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Adolescent; Child; Factor VIIa administration and dosage; Factor VIIa adverse effects; Hemorrhage blood; Infant; Transfusion

Indexed keywords

FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHILD; CHILDHOOD INJURY; CHILDHOOD MORTALITY; CRYOPRECIPITATE; DEEP VEIN THROMBOSIS; DRUG RESPONSE; ERYTHROCYTE TRANSFUSION; EXTRACORPOREAL OXYGENATION; HEART SURGERY; HEMATOLOGY; HUMAN; INFANT; LIVER DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; OFF LABEL DRUG USE; ONCOLOGY; PEDIATRICS; PH; POSTOPERATIVE HEMORRHAGE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; THROMBOCYTE TRANSFUSION; THROMBOEMBOLISM;

EID: 84861899380     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-2561     Document Type: Article

References (32)

1. Hedner U. Mechanism of action of recombinant activated factor VII: an update. Semin Hematol. 2006;43(1 suppl 1):S105-S107 (Pubitemid 43150511)
2. Cameron P, Phillips L, Balogh Z, et al. The use of recombinant activated factor VII in trauma patients: experience from the Australian and New Zealand haemostasis registry. Injury. 2007;38(9):1030-1038 (Pubitemid 47277405)
3. Dunkley S, Phillips L, McCall P, et al. Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry. Ann Thorac Surg. 2008;85(3):836-844 (Pubitemid 351255532)
4. Phillips LE, McLintock C, Pollock W, et al Australian and New Zealand Haemostasis Registry. Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry. Anesth Analg. 2009;109(6):1908-1915
5. Tobias JD, Berkenbosch JW, Russo P. Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant. Pediatr Crit Care Med. 2003;4(1):49-51
6. Verrijckt A, Proulx F, Morneau S, Vobecky S. Activated recombinant factor VII for refractory bleeding during extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg. 2004;127(6):1812-1813 (Pubitemid 38725466)
7. Cetin H, Yalaz M, Akisu M, Karapinar DY, Kavakli K, Kultursay N. The use of recombinant activated factor VII in the treatment of massive pulmonary hemorrhage in a preterm infant. Blood Coagul Fibrinolysis. 2006;17(3):213-216
8. Jen H, Shew S. Recombinant activated factor VII use in critically ill infants with active hemorrhage. J Pediatr Surg. 2008;43(12):2235-2238
9. Alten JA, Benner K, Green K, Toole B, Tofil NM, Winkler MK. Pediatric off-label use of recombinant factor VIIa. Pediatrics. 2009; 123(3):1066-1072
10. Egan JR, Lammi A, Schell DN, Gillis J, Nunn GR. Recombinant activated factor VII in paediatric cardiac surgery. Intensive Care Med. 2004;30(4):682-685 (Pubitemid 38530106)
11. Tobias JD, Simsic JM, Weinstein S, Schechter W, Kartha V, Michler R. Recombinant factor VIIa to control excessive bleeding following surgery for congenital heart disease in pediatric patients. J Intensive CareMed. 2004;19(5):270-273
12. Agarwal HS, Bennett JE, Churchwell KB, et al. Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg. 2007;84(1):161-168 (Pubitemid 46921117)
13. Vick LR, Islam S. Recombinant factor VIIa as an adjunct in nonoperative management of solid organ injuries in children. J Pediatr Surg. 2008;43(1):195-198, discussion 198-199
14. Heisel M, Nagib M, Madsen L, Alshiekh M, Bendel A. Use of recombinant factor VIIa (rFVIIa) to control intraoperative bleeding in pediatric brain tumor patients. Pediatr Blood Cancer. 2004;43(6):703-705 (Pubitemid 39411228)
15. Hartmann M, Sucker C, Messing M. Recombinant activated factor VII in the treatment of near-fatal bleeding during pediatric brain tumor surgery. Report of two cases and review of the literature. J Neurosurg. 2006;104(suppl 1):55-58 (Pubitemid 44954863)
16. Herbertson M, Kenet G. Applicability and safety of recombinant activated factor VII to control non-haemophilic haemorrhage: investigational experience in 265 children. Haemophilia. 2008;14(4):753-762 (Pubitemid 352016031)
17. Warren OJ, Rogers PL, Watret AL, et al. Defining the role of recombinant activated factor VII in pediatric cardiac surgery: where should we go from here? Pediatr Crit Care Med. 2009;10(5):572-582
18. Villar A, Aronis S, Morfini M, et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia. 2004;10(4):352-359 (Pubitemid 39077035)
19. Shapiro AD. Recombinant factor VIIa in the treatment of bleeding in hemophilic children with inhibitors. Semin Thromb Hemost. 2000;26(4):413-419
20. Klitgaard T, Nielsen TG. Overview of the human pharmacokinetics of recombinant activated factor VII. Br J Clin Pharmacol. 2008;65(1):3-11 (Pubitemid 350265177)
21. Ekert H, Brizard C, Eyers R, Cochrane A, Henning R. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coagul Fibrinolysis. 2006;17(5):389-395 (Pubitemid 43941581)
22. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood. 2004;104(13): 3858-3864 (Pubitemid 39620130)
23. Pusateri AE, Park MS. Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma. Crit Care. 2005;9 (suppl 5):S15-S24 (Pubitemid 43173684)
24. Pychyńska-Pokorska M, Pagowska-Klimek I, Krajewski W, Moll JJ. Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2011;25(6):987-994
25. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295(3):293-298 (Pubitemid 43112957)
26. Ranucci M, Isgrò G, Soro G, Conti D, De Toffol B. Efficacy and safety of recombinant activated factor vii in major surgical procedures: systematic review and meta-analysis of randomized clinical trials. Arch Surg. 2008;143(3):296-304 (Pubitemid 351439290)
27. Niebler RA, Punzalan RC, Marchan M, Lankiewicz MW. Activated recombinant factor VII for refractory bleeding during extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2010;11(1):98-102
28. Riccabona M, Kuttnig-Haim M, Dacar D, et al. Venous thrombosis in and after extracorporeal membrane oxygenation: detection and follow-up by color Doppler sonography. Eur Radiol. 1997;7(9):1383-1386 (Pubitemid 127538373)
29. Alexander DC, Bundy DG, Shore AD, Morlock L, Hicks RW, Miller MR. Cardiovascular medication errors in children. Pediatrics. 2009;124(1):324-332
30. Wong IC, Ghaleb MA, Franklin BD, Barber N. Incidence and nature of dosing errors in paediatric medications: a systematic review. Drug Saf. 2004;27(9):661-670 (Pubitemid 38980451)
31. Lesar TS. Tenfold medication dose prescribing errors. Ann Pharmacother. 2002; 36(12):1833-1839 (Pubitemid 35429550)
32. Chedoe I, Molendijk HA, Dittrich ST, et al. Incidence and nature of medication errors in neonatal intensive care with strategies to improve safety: a review of the current literature. Drug Saf. 2007;30(6):503-513 (Pubitemid 46873075)